# US 2013/0156793 A1 · Insulin-resistance-improving drug > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156793 A1 - Document ID: US20130156793A1 - Status: Published application - Kind: A1 - Application number: 13/699,876 - Filed: 2011-05-27 - Published: 2013-06-20 - Earliest claimed: 2010-05-27 - Assignees: Sekisui Medical Co., Ltd.; The University of Tokyo - Inventors: Takashi Kadowaki; Kohjiro Ueki; Yukiko Okazaki; Matthias Bluher; Sumiko Ozawa - Web page: https://patentgrep.com/patent/US20130156793A1 ## CPC - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61K 31/00: Medicinal preparations containing organic active ingredients - A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters - A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) - C07K 16/18: against material from animals or humans - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - C12Q 1/686: Polymerase chain reaction [PCR] - G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics} - G01N 33/6893: {related to diseases not provided for elsewhere} - A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered} - A61K 2039/505: {comprising antibodies} - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C12N 2310/14: interfering nucleic acids [NA] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of FSTL3. Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3. ## Claims ### Claim 1 An insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient. ### Claim 2 (depends on 1) The insulin resistance improving drug according to claim 1, wherein the FSTL3 inhibitor is any one of: (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3; (B) an inhibitor for expression of FSTL3; and (C) a competitor of FSTL3. ### Claim 3 (depends on 2) An insulin resistance improving drug comprising (A), (B), or (C) of claim 2 and a pharmaceutically acceptable diluent or carrier. ### Claim 4 (depends on 2) Use of one or more of (A), (B), and (C) of claim 2 in the manufacture of a medicament for inhibiting FSTL3. ### Claim 5 (depends on 2) Use of one or more of (A), (B), and (C) of claim 2 in the manufacture of a composition used for a treatment of insulin resistance in animal or human. ### Claim 6 A method of screening a compound for preventing or treating obesity or insulin resistance comprising the steps of: (1) bringing a test compound into contact with FSTL3-expressing cells; and (2) confirming whether the test compound improves inhibition of signal transduction due to FSTL3. ### Claim 7 (depends on 2) The insulin resistance improving drug according to claim 2, wherein the (A) substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3 is an antibody. ### Claim 8 (depends on 2) The insulin resistance improving drug according to claim 2, wherein the (A) substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3 is activin A, activin B, or activin AB. ### Claim 9 (depends on 2) The insulin resistance improving drug of claim 2, wherein the (B) inhibitor for expression of FSTL3 is an antisense oligonucleotide. ### Claim 10 A method for improving insulin resistance comprising: the step of administering an FSTL3 inhibitor.